Cygnus nicotine patch
NDA for the transdermal patch developed for Pharmacia Leo, makers of Nicorette chewing gum, will be filed in "a matter of weeks," President and CEO David de Weese told a Robertson Stephens Medical Conference in New York City Nov. 27. De Weese stressed that the clinical endpoint of Phase III studies of the patch was "total abstenince" verified by checking patient respiration, saliva, and serum. "When looking at clinical data from the competition, I would ask you to keep that in mind," he added. Elan filed an NDA for Nicolan in August 1989, and Marion Merrell Dow expects to file an NDA for Alza's transdermal nicotine in the first quarter of 1990 ("The Pink Sheet" Oct. 29, p. 16).
You may also be interested in...
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.